Institute Prof. Robert Langer, whose “innovations have helped create more than 100 products from artificial skin to messenger RNA (mRNA) vaccines,” speaks with Guardian reporter Zoë Corbyn. “I think it’s important to stress how much engineers can and have changed the world for the better,” says Langer. “It’s a thrill for me to see engineering and biology improving people’s lives; that’s been my dream from the beginning.”
Researchers from MIT and the La Jolla Institute for Immunology have found a vaccine ingredient that may strengthen immune response, reports Natalie Colarossi for Newsweek. This combination-style vaccine ingredient “may boost the effectiveness of inoculations ranging from HIV to Covid-19,” writes Colarossi.
A new study co-authored by Prof. Retsef Levi finds vaccine passports “that exempt vaccinated people from regular Covid-19 testing would allow many infections to be missed,” reports Nancy Lapid for Reuters.
Forbes reporter Jack Kelly profiles Institute Prof. Robert Langer, spotlighting his career journey and his passion for helping others. “I traded job security and high pay for doing things I was passionate about,” Langer explains. “Out of over 20 job offers I received upon graduation from college, I chose the lowest paying one by far because I thought by doing so, I could potentially improve the health of patients. I dreamed about doing things that I thought would make the world a better place.”
Writing for the NIH Director’s Blog, Dr. Francis Collins highlights how Prof. Tyler Jacks and research scientist Megan Burger’s work exploring T cell exhaustion led to the creation of a “strategy for developing cancer vaccines that can ‘awaken’ T cells and reinvigorate the body’s natural cancer-fighting abilities.” Collins writes that “the researchers hope to learn if this approach to cancer vaccines might work even better when used in combination with immunotherapy drugs, which unleash the immune system against cancer in other ways.”
Noubar Afeyan ’87, a member of the MIT Corporation, speaks to Guy Raz of NPR’s How I Built This podcast about his journey toward co-founding Moderna and becoming a part of history through the rapid creation and production of vaccines for the Covid-19 pandemic. “The reality is when you have a pandemic and you’re a public company and you have material data, our sense was that we at a high level had to put that [information] out there,” says Afeyan. “One of these things we learned, because none of us had been in this situation before, is that we are going to get criticized no matter what we did. So, we just had to do what we thought was right.”
Nature reporter Eric Bender spotlights MIT startup Kytopen, which has developed a microfluidic platform to create induced pluripotent stem (iPS) cells and other forms of cell therapy. We want to do minimally invasive surgery,” says Kytopen co-founder Prof. Cullen Buie.
Prof. Jonathan Gruber speaks with Margery Eagan and Jared Bowen on Boston Public Radio about the ethics of offering vaccine booster shots in the U.S. when many nations are struggling with vaccine scarcity. “This is really a moment where, going forward, the world has to figure out a more effective strategy,” said Gruber. “We need to think about how we’re going to set up institutions to deal with these kinds of tradeoffs in the future.”
National Geographic reporter Roxanne Khamsi spotlights how Prof. Richard Braatz is working on developing continuous manufacturing processes that could help boost global vaccine availability. Khamsi notes that one feature Braatz and his colleagues are testing is using “a filter that attaches to the side of their production tanks to continuously extract vaccine material, rather than harvesting it in bulk.”
As part of the Vax India Now event on CNN, Profs. Bruce Walker, Peko Hosoi and Parag Pathak, along with senior research scientist Chris Caplice and MIT Medical Director Cecilia Stuopis, participate in a discussion led by Vijay Joshi, Editor-in-Chief of The Press Trust of India, about what India can learn from America’s experience with vaccine distribution. “It is absolutely [in the U.S.’s] interest to make sure that everybody in India gets vaccinated, that everybody in South America get vaccinated,” says Hosoi. “We really are all in this together.”
A new study by Prof. Jeffrey Harris finds that the extensive research invested in developing a vaccine for HIV has contributed to the successful development of Covid-19 vaccines, writes Derek Thompson for The Atlantic. Nearly 90 percent of COVID-19 vaccines that made it to clinical trials used technology that “could be traced back to prototypes tested in HIV vaccine trials,” Harris found.
Michelle Penn-Marshall, vice president for research at Hampton University, speaks with ABC News reporter Jade Lawson about how Hampton consulted with MIT researchers on the design of a mobile Covid-19 vaccination unit. "MIT was the first school to have a mobile unit. I contacted MIT when I saw that in the news this summer and said, 'Hey, how can we do this?' They took the time and gave me a one-hour briefing on the mobile unit, and also they gave me information regarding testing efficiency," says Penn-Marshall.
"You remember when we go to election polls, the voting booth, during elections, we get a little sticker that says 'I Voted'" says Prof. Sinan Aral of a new study that finds hearing about people who have received the Covid-19 vaccine can increase vaccine acceptance rates. "You should think of this as a very similar type of strategy. The reason we get that sticker that says 'I Voted' is that social proof motivates people to join in. And so if we got a sticker or put out a video or put out a message that said, 'I got vaccinated,' it would have the same effect for the same reasons."
New Yorker reporter Benjamin Wallace-Wells spotlights new research from the MIT Initiative on the Digital Economy, which shows “just telling people the accurate immunization rates in their country increased, by five per cent, the number who said that they would get the vaccine.”
In a letter to the editor that appeared in The New York Times, senior lecturer Jonathan Byrnes advocates for a continuous flow of vaccinations to quickly protect the population against Covid-19. “We need two things: 1) a core of highly experienced supply chain managers supplementing the public health professionals; and 2) a management structure, probably under the Defense Production Act, to coordinate, organize and manage the supply chain,” Byrnes writes.